Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MKC1106-MT in advanced melanoma
NCT01026051Phase 2Terminated
- Sponsor
- MannKind
- Start
- Oct 2010
- Primary completion
- Sep 2011
- Modality
- Prophylactic Vaccines, Peptides, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MKC1106-MT in melanoma, sponsored by MannKind. Started Oct 2010; status: terminated.
02
Drugs
MKC1106-MT
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01026051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01026051.